These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

990 related articles for article (PubMed ID: 21219187)

  • 1. Immune response to dengue virus and prospects for a vaccine.
    Murphy BR; Whitehead SS
    Annu Rev Immunol; 2011; 29():587-619. PubMed ID: 21219187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice.
    Zellweger RM; Tang WW; Eddy WE; King K; Sanchez MC; Shresta S
    J Virol; 2015 Jun; 89(12):6494-505. PubMed ID: 25855749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.
    Uno N; Ross TM
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33208445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development.
    Elong Ngono A; Shresta S
    Front Immunol; 2019; 10():1316. PubMed ID: 31244855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.
    Briggs CM; Smith KM; Piper A; Huitt E; Spears CJ; Quiles M; Ribeiro M; Thomas ME; Brown DT; Hernandez R
    J Virol; 2014 Jun; 88(12):6729-42. PubMed ID: 24696467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
    Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
    BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dengue virus vaccine development.
    Yauch LE; Shresta S
    Adv Virus Res; 2014; 88():315-72. PubMed ID: 24373316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focused dengue vaccine development: outwitting nature's design.
    Kudlacek ST; Metz SW
    Pathog Dis; 2019 Feb; 77(1):. PubMed ID: 30726906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
    Simmons M; Burgess T; Lynch J; Putnak R
    Virology; 2010 Jan; 396(2):280-8. PubMed ID: 19913867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
    Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG
    Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dengue vaccine candidates in development.
    Durbin AP; Whitehead SS
    Curr Top Microbiol Immunol; 2010; 338():129-43. PubMed ID: 19802583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-Cell Analysis of B Cell/Antibody Cross-Reactivity Using a Novel Multicolor FluoroSpot Assay.
    Hadjilaou A; Green AM; Coloma J; Harris E
    J Immunol; 2015 Oct; 195(7):3490-6. PubMed ID: 26320246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.
    Acosta EG; Bartenschlager R
    Expert Rev Vaccines; 2016; 15(4):467-82. PubMed ID: 26577689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.
    Sjatha F; Kuwahara M; Sudiro TM; Kameoka M; Konishi E
    Microbiol Immunol; 2014 Feb; 58(2):126-34. PubMed ID: 24372832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying protective dengue vaccines: guide to mastering an empirical process.
    Halstead SB
    Vaccine; 2013 Sep; 31(41):4501-7. PubMed ID: 23896423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes.
    Holman DH; Wang D; Raviprakash K; Raja NU; Luo M; Zhang J; Porter KR; Dong JY
    Clin Vaccine Immunol; 2007 Feb; 14(2):182-9. PubMed ID: 17192403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
    Osorio JE; Wallace D; Stinchcomb DT
    Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.